The purpose behind the pipeline
Our team of experts across the entire spectrum of drug development powers solutions designed to impact patients’ lives.
The safety and efficacy of the following investigational compounds or investigational uses of marketed products have not been established. These uses have not been approved by the U.S. Food and Drug Administration or other regulatory authorities unless otherwise noted.
BioLineRx’s focused pipeline includes novel compounds with best-in-class potential to meet areas of unmet need for patients with cancer and rare diseases.
Our lead asset, motixafortide, is an innovative, high-affinity CXCR4 inhibitor. This novel agent leverages the expression of the CXCR4 receptor in a variety of cell populations, including hematopoietic stem cells, immune cells, and cancer cells, making it potentially applicable to multiple indications, such as stem cell mobilization and anti-tumor therapy.